Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-103 in Adult Patients With Mesothelin-Expressing Advanced or Metastatic Solid Tumors

Next Previous
Trial Profile

An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-103 in Adult Patients With Mesothelin-Expressing Advanced or Metastatic Solid Tumors

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 12 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NIB 103 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Takeda

Most Recent Events

  • 09 Jun 2025 According to a NoileImmune media release, company announces that it has submitted a Clinical Trial Notification (CTN) of NIB103 phase I clinical trial for solid cancers in Japan which Noile Immune newly launched (hereinafter referred to as the Trial) to the Pharmaceuticals and Medical Devices Agency (PMDA) and that the required investigation by PMDA has been completed.
  • 29 May 2025 Status changed from active, no longer recruiting to discontinued. Reason the study was stopped: Business decision unrelated to patient safety
  • 20 Dec 2023 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top